All In Biotech

Drug Trial Radar · NCT02654912

Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration

Community-led Responses for Elimination (CoRE): A Cluster Randomized Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration in Malaria Elimination Areas in Southern Province Zambia

Last checked: Nov 20, 2026Latest source record: Feb 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 8,682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,682

Actual

Start

Feb 2016

Primary completion

Jun 2020

Study completion Jul 2020

Sponsor

Lead sponsor
PATHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Zambia; AKROS Global Health
First posted
Jan 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 3 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to compare the effectiveness of reactive focal drug administration (RFDA) using dihydroartemisinin+piperaquine (DHAP) versus reactive focal test and treat (RFTAT) using artemether+lumefantrine (AL) as a routine process for identifying and eliminating malaria transmission as measured through achieving zero seropositivity in children under five in Southern Province, Zambia. These two strategies are potential candidates for expanded malaria operational surveillance and elimination for low malaria transmission areas.

Conditions

  • Malaria

Interventions

  • Reactive Focal Drug AdministrationDrug

    This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Malaria seropositivity in children under fiveTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Southern province medical office

    Choma, Southern Province, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.